title: Significance of VH genes mutation status for prognosis of CLL patients.
abstract: OBJECTIVE
  The aim of this study was to evaluate significance of VH mutation status for prognosis of B-cell chronic lymphocytic leukemia (B-CLL) patients in comparison with other prognostic markers.
  
  
  METHODS
  The VH mutation status was evaluated in 43 B-CLL patients by RT-PCR amplification and nucleotide sequencing, and CD38 expression - by two-color FACS analysis. The prognostic influence of VH mutation rate and CD38 expression level was tested by different statistical methods.
  
  
  RESULTS
  The increasing number of advanced cases over the follow-up period, shorter median time from diagnosis to start of second line therapy, worse response to fludarabine treatment, poor survival for early stages B-CLL were found in unmutated versus mutated CLL patients. The significance of CD38 expression for CLL prognosis was revealed as predictor for response for fludarabine treatment and time of progression in advanced stages. The correlation between CD38 expression and VH mutation status was not found.
  
  
  CONCLUSIONS
  Simultaneous determination of VH mutation status and CD38 expression may be helpful for prediction of CLL prognosis.
authors.affiliation: Scientific Research Centre for Radiation Medicine, AMS of Ukraine, Kyiv, Ukraine. nbilous@yahoo.com
authors.forename: N
authors.initials: N
authors.lastname: Bilous
authors.forename: I
authors.initials: I
authors.lastname: Abramenko
authors.forename: I
authors.initials: I
authors.lastname: Kryachok
authors.forename: D
authors.initials: D
authors.lastname: Bazyka
authors.forename: A
authors.initials: A
authors.lastname: Chumak
authors.forename: V
authors.initials: V
authors.lastname: Bebeshko
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000096:biosynthesis; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics*; D007135:Immunoglobulin Variable Region / Q000235:genetics*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D007143:Immunoglobulin Heavy Chains; D007135:Immunoglobulin Variable Region; D051997:ADP-ribosyl Cyclase 1; D014740:Vidarabine; C024352:fludarabine